Compare Mesoblast Limited (MESO) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Mesoblast Limited trades at $16.8 (market cap $2.21B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.78. The key difference: Mesoblast Limited is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MESO | QDTY | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $20.96 | $46.71 |
52-Week Low | $12.88 | $36.57 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
QDTY trades at $39.75, showing minimal daily movement with a -0.13% decline. The technical picture remains neutral overall with bearish moving averages, while the company demonstrates consistent dividend distributions through its weekly payout structure. Recent YieldMax ETF announcements highlight ongoing distribution activities through mid-2026.
The stock presents income-focused appeal through regular distributions, though fundamental metrics remain unavailable for comprehensive valuation assessment. Key considerations include reliance on ETF distribution strategies and market volatility exposure. The neutral technical stance suggests limited near-term directional momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
